RxDoctor Payments Data

Lindsay Jobe

Family · Greensburg, INNPI 1124567326

Payments from drug & device makers

$1,062in general payments, 2019–2025

Across 70 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$394
  • Incyte Corporation$99
  • Pfizer$96
  • Novo Nordisk$72
  • Takeda Pharmaceuticals U.S.A., Inc.$67
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$62
  • plus $272 from 12 others

What the payments were for

  • Food & beverage$96391%
  • Education$999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,062 in reported general payments places this provider in the 65th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$4,687
Medicare patients
37
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$57,699
VraylarCariprazine Hcl24$33,688
TrulicityDulaglutide19$18,755
XareltoRivaroxaban20$18,270
EliquisApixaban24$16,670
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,438
FarxigaDapagliflozin Propanediol12$9,668
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$4,308
Breo ElliptaFluticasone/Vilanterol11$3,884
Pregabalin51$2,466
Gabapentin130$1,937
Venlafaxine Hcl ErVenlafaxine Hcl42$1,710
Omega-3 Acid Ethyl Esters20$1,542
Omeprazole85$1,196
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen72$1,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$72$57,69959 claims
AbbVieVraylar$394$33,68824 claims
Lilly USA, LLCTrulicity$28$18,75519 claims
PfizerEliquis$96$16,67024 claims
GSKTrelegy Ellipta, Breo Ellipta$37$14,32227 claims
AstraZenecaFarxiga$27$9,66812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,392 family providers in Indiana.

Other family in Greensburg

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →